

Joseph C Cappelleri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2196363/publications.pdf>

Version: 2024-02-01

151
papers

10,800
citations

87888

38
h-index

32842

100
g-index

154
all docs

154
docs citations

154
times ranked

11332
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 353-363.	1.1	2
2	Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1449-1458.	2.2	22
3	Patient and caregiver preferences on treatment attributes for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2225-2233.	2.2	9
4	Concern about addiction is associated with lower quality of life in patients with osteoarthritis: an exploratory, real-world data analysis. <i>Quality of Life Research</i> , 2022, 31, 185-191.	3.1	3
5	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. <i>European Journal of Pain</i> , 2022, 26, 648-667.	2.8	7
6	Validation of Patient Identification Algorithms for Atopic Dermatitis Using Healthcare Databases. <i>Dermatology and Therapy</i> , 2022, 12, 545-559.	3.0	2
7	Satisfaction with Medications Prescribed for Osteoarthritis: A Cross-Sectional Survey of Patients and Their Physicians in the United States. <i>Pain and Therapy</i> , 2022, 11, 191-208.	3.2	3
8	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. <i>Journal of Rheumatology</i> , 2022, 49, 615-621.	2.0	8
9	Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey. <i>Rheumatology and Therapy</i> , 2022, 9, 823-838.	2.3	1
10	Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies. <i>Journal of Dermatological Treatment</i> , 2022, , 1-28.	2.2	1
11	Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis. <i>Future Cardiology</i> , 2022, 18, 393-405.	1.2	9
12	Care pathways in atopic dermatitis: a retrospective <sc>population-based</sc> cohort study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1456-1466.	2.4	4
13	Factors associated with physician-reported treatment status of patients with osteoarthritis pain. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, .	1.9	1
14	Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database Analysis. <i>Advances in Therapy</i> , 2022, 39, 4157-4168.	2.9	3
15	Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab. <i>Osteoarthritis and Cartilage Open</i> , 2022, 4, 100294.	2.0	1
16	Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1096-1106.	1.9	15
17	Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 983-993.	1.9	6
18	Pain severity and healthcare resource utilization in patients with osteoarthritis in the United States. <i>Postgraduate Medicine</i> , 2021, 133, 10-19.	2.0	18

#	ARTICLE	IF	CITATIONS
19	Effects of dose titration on adherence and treatment duration of pregabalin among patients with neuropathic pain: A MarketScan database study. <i>PLoS ONE</i> , 2021, 16, e0242467.	2.5	3
20	Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. <i>Journal of Medical Economics</i> , 2021, 24, 279-290.	2.1	7
21	Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD. <i>Dermatology and Therapy</i> , 2021, 11, 221-233.	3.0	12
22	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	3.5	9
23	An indirect comparison between bosutinib, nilotinib and dasatinib in first-line chronic phase chronic myeloid leukemia. <i>Current Medical Research and Opinion</i> , 2021, 37, 801-809.	1.9	3
24	Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. <i>Current Medical Research and Opinion</i> , 2021, 37, 891-902.	1.9	5
25	Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 603-612.	1.4	4
26	Diagnostic accuracy of patient-reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis. <i>GastroHep</i> , 2021, 3, 161-168.	0.6	2
27	Addressing Bias in Responder Analysis of Patient-Reported Outcomes. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 989-1000.	1.6	7
28	SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. <i>BMJ Open</i> , 2021, 11, e045105.	1.9	65
29	Further reduction in statistical power for responder analysis of patient-reported outcomes with measurement error. <i>Journal of Clinical Epidemiology</i> , 2021, 140, 200-201.	5.0	1
30	Development of a New Patient-Reported Medication Adherence Instrument: Concerns Influencing Medication Adherence. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1991-2007.	1.8	4
31	Itch as Major Mediator of Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4081.	2.4	3
32	Response to the Letter to the Editor Regarding "Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis". <i>Dermatology and Therapy</i> , 2021, 11, 2241-2244.	3.0	0
33	Clinical and Economic Burden of Pediatric Mild-to-Moderate Atopic Dermatitis: A Population-Based Nested Case-Control Study in Sweden. <i>Dermatology and Therapy</i> , 2021, 11, 161-172.	3.0	6
34	Symptom burden of patients with moderate-to-severe atopic dermatitis. <i>European Journal of Dermatology</i> , 2021, 31, 752-758.	0.6	3
35	Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. <i>Journal of Medical Economics</i> , 2020, 23, 415-427.	2.1	11
36	Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 1202-1213.	1.3	31

#	ARTICLE	IF	CITATIONS
37	Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. <i>Future Oncology</i> , 2020, 16, 3107-3116.	2.4	5
38	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020, 93, 100601.	1.2	10
39	Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2020, 10, 681-694.	3.0	20
40	<p>Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 949-961.	1.8	10
41	Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database. <i>Dermatology and Therapy</i> , 2020, 10, 791-806.	3.0	22
42	Considerations for development of an evidence dossier to support the use of mobile sensor technology for clinical outcome assessments in clinical trials. <i>Contemporary Clinical Trials</i> , 2020, 91, 105962.	1.8	34
43	<p>Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2020, Volume 12, 57-67.	1.9	2
44	<p>A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States</p>. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020, Volume 13, 259-266.	1.8	36
45	The Inflammatory Bowel Disease Questionnaire in Randomized Controlled Trials of Treatment for Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>Journal of Patient-centered Research and Reviews</i> , 2020, 7, 189-205.	0.9	22
46	Multimodal Treatment Patterns for Osteoarthritis and Their Relationship to Patient-Reported Pain Severity: A Cross-Sectional Survey in the United States. <i>Journal of Pain Research</i> , 2020, Volume 13, 3415-3425.	2.0	17
47	Systematic review and network meta-analysis of first-line therapy for advancedEGFR-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2857-2871.	2.4	17
48	<p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. <i>Clinical and Experimental Gastroenterology</i> , 2019, Volume 12, 263-278.	2.3	27
49	The International Index of Erectile Function (IIEF) â€“ A Systematic Review of Measurement Properties. <i>Journal of Sexual Medicine</i> , 2019, 16, 1861-1862.	0.6	2
50	<p>Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 551-565.	1.9	7
51	<p>Patient and economic burdens of postherpetic neuralgia in China</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 539-550.	1.9	19
52	The Epidemiology of Herpes Zoster and Postherpetic Neuralgia in China: Results from a Cross-Sectional Study. <i>Pain and Therapy</i> , 2019, 8, 249-259.	3.2	61
53	Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Advances in Therapy</i> , 2019, 36, 2147-2160.	2.9	14
54	Guest editorial summary on articles selected from the 2018 International Conference on Health Policy Statistics. <i>Health Services and Outcomes Research Methodology</i> , 2019, 19, 1-7.	1.8	0

#	ARTICLE	IF	CITATIONS
55	Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia. <i>Current Medical Research and Opinion</i> , 2019, 35, 1615-1622.	1.9	13
56	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broadenâ€”a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2019, 5, e000806.	3.8	44
57	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , 2019, 5, e000808.	3.8	46
58	Clinically important difference on the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire in patients with erectile dysfunction. <i>International Journal of Clinical Practice</i> , 2018, 72, e13073.	1.7	10
59	Enriching the Interpretation of the Erectile Dysfunction Inventory of Treatment Satisfaction: Characterizing Success in Treatment Satisfaction. <i>Journal of Sexual Medicine</i> , 2018, 15, 732-740.	0.6	3
60	Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 145-156.	1.3	80
61	Interpreting the Effectiveness of Opioids and Pregabalin for Pain Severity, Pain Interference, and Fatigue in Fibromyalgia Patients. <i>Pain Practice</i> , 2018, 18, 611-624.	1.9	2
62	Psychometric validation of the SF-36Â® Health Survey in ulcerative colitis: results from a systematic literature review. <i>Quality of Life Research</i> , 2018, 27, 273-290.	3.1	29
63	Factors Related to the Use of Topical vs. Oral NSAIDs for Sprains, Strains, and Contusions in a Senior Population: A Retrospective Analysis of Administrative Claims Data. <i>Drugs and Aging</i> , 2018, 35, 937-950.	2.7	3
64	Validation of the Itch Severity Item as a Measurement Tool for Pruritus in Patients with Psoriasis: Results from a Phase 3 Tofacitinib Program. <i>Acta Dermato-Venereologica</i> , 2018, 98, 340-345.	1.3	20
65	The economic and clinical burden of early versus late initiation of celecoxib among patients with osteoarthritis. <i>ClinicoEconomics and Outcomes Research</i> , 2018, Volume 10, 213-222.	1.9	6
66	Important Group Differences on the Functional Assessment of Cancer Therapyâ€”Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418.	0.3	7
67	Patient-Reported Outcome Measures: Development and Psychometric Evaluation. <i>ICSA Book Series in Statistics</i> , 2018, , 317-346.	0.2	3
68	Advancing Interpretation of Patient-Reported Outcomes. <i>ICSA Book Series in Statistics</i> , 2018, , 69-89.	0.2	1
69	Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis. <i>American Health and Drug Benefits</i> , 2018, 11, 408-417.	0.5	12
70	Response to Editorial Comment: â€œQuantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Mapsâ€• <i>Journal of Sexual Medicine</i> , 2017, 14, 162.	0.6	0
71	Reflections on ISPORâ€™s Clinician-Reported Outcomes Good Measurement Practice Recommendations. <i>Value in Health</i> , 2017, 20, 15-17.	0.3	2
72	Quantifying Barriers to Improvement of Treatment Satisfaction in Men with Erectile Dysfunction: Use of Person-Item Maps. <i>Journal of Sexual Medicine</i> , 2017, 14, 152-159.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Characterizing neuropathic pain profiles: enriching interpretation of painDETECT. Patient Related Outcome Measures, 2016, Volume 7, 93-99.	1.2	14
74	Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis, 2016, 10, 1310-1315.	1.3	16
75	Simplified Interpretation of the Erectile Function Domain of the International Index of Erectile Function. Journal of Sexual Medicine, 2016, 13, 690-696.	0.6	8
76	MAPPING THE WESTERN ONTARIO AND MCMASTER UNIVERSITIES ARTHRITIS INDEX (WOMAC) TO THE EQ-5D. Value in Health, 2016, 19, A235-A236.	0.3	2
77	Best (but oft-forgotten) practices: expressing and interpreting associations and effect sizes in clinical outcome assessments. American Journal of Clinical Nutrition, 2016, 103, 685-693.	4.7	27
78	Interpreting Change in Scores on Patient-Reported Outcome Instruments. Therapeutic Innovation and Regulatory Science, 2016, 50, 22-29.	1.6	71
79	Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis. American Health and Drug Benefits, 2016, 9, 84-93.	0.5	36
80	A conversation with Joseph Lau. Research Synthesis Methods, 2015, 6, 2-20.	8.7	3
81	A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine. BMC Health Services Research, 2015, 15, 159.	2.2	10
82	Advances in Clinical Outcome Assessments. Therapeutic Innovation and Regulatory Science, 2015, 49, 780-782.	1.6	4
83	Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses. Journal of Dermatological Treatment, 2015, 26, 121-123.	2.2	32
84	A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization. Rheumatology International, 2015, 35, 1837-1849.	3.0	20
85	The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib. Journal of Dermatological Treatment, 2015, 26, 19-22.	2.2	31
86	Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes. BMC Gastroenterology, 2015, 15, 14.	2.0	76
87	Interpretation of patient-reported outcomes. Statistical Methods in Medical Research, 2014, 23, 460-483.	1.5	61
88	Evaluating methodological assumptions in comparative effectiveness research: overcoming pitfalls. Journal of Comparative Effectiveness Research, 2014, 3, 79-93.	1.4	4
89	Further Understanding of the International Index of Erectile Function at 15+ Years: Confirmatory Factor Analysis and Multidimensional Scaling. Therapeutic Innovation and Regulatory Science, 2014, 48, 246-254.	1.6	4
90	Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens. Menopause, 2014, 21, 815-822.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Impact of physician specialty on classification of physician-perceived patient severity for patients with osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2014, 22, 647-651.	1.3	3
92	Indirect Treatment Comparison/Network Meta-Analysis Study Questionnaire to Assess Relevance and Credibility to Inform Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report. <i>Value in Health</i> , 2014, 17, 157-173.	0.3	248
93	Overview of Classical Test Theory and Item Response Theory for the Quantitative Assessment of Items in Developing Patient-Reported Outcomes Measures. <i>Clinical Therapeutics</i> , 2014, 36, 648-662.	2.5	367
94	Revisiting issues, drawbacks and opportunities with observational studies in comparative effectiveness research. <i>Journal of Evaluation in Clinical Practice</i> , 2013, 19, 579-583.	1.8	8
95	Cumulative response curves to enhance interpretation of treatment differences on the Self-Esteem And Relationship questionnaire for men with erectile dysfunction. <i>BJU International</i> , 2013, 111, E115-E120.	2.5	9
96	Using the probability-probability plot and index to augment interpretation of treatment effect for patient-reported outcome measures. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 707-713.	1.4	1
97	Estimating the economic benefits of positive shifts in fibromyalgia severity: an exploratory analysis based on modeling of clinical trial data of pregabalin. <i>Journal of Medical Economics</i> , 2013, 16, 55-61.	2.1	3
98	Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 2207-2217.	1.0	5
99	Multi-domain Longitudinal Modeling: An Application to the International Index of Erectile Function. <i>Therapeutic Innovation and Regulatory Science</i> , 2013, 47, 57-64.	1.6	2
100	The burden associated with neuropathic pain in Western Europe. <i>Journal of Medical Economics</i> , 2013, 16, 85-95.	2.1	108
101	Assessment of measurement properties of peak VO ₂ in children with pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2012, 12, 54.	2.0	8
102	Health Care Costs in Patients with Painful Diabetic Peripheral Neuropathy Prescribed Pregabalin or Duloxetine. <i>Pain Practice</i> , 2012, 12, 209-218.	1.9	7
103	Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2. <i>Value in Health</i> , 2011, 14, 429-437.	0.3	606
104	Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. <i>Value in Health</i> , 2011, 14, 417-428.	0.3	822
105	Considerations on the Use of Patient-Reported Outcomes in Comparative Effectiveness Research. <i>Journal of Managed Care Pharmacy</i> , 2011, 17, S27-S33.	2.2	7
106	Examination of Data, Analytical Issues and Proposed Methods for Conducting Comparative Effectiveness Research Using "Real-World Data". <i>Journal of Managed Care Pharmacy</i> , 2011, 17, 1-37.	2.2	2
107	Applying area-under-the-curve analysis to enhance interpretation of response profiles: an application to sleep quality scores in patients with fibromyalgia. <i>Quality of Life Research</i> , 2011, 20, 491-498.	3.1	10
108	Understanding the Effects of Sildenafil Treatment on Erection Maintenance and Erection Hardness. <i>Journal of Sexual Medicine</i> , 2010, 7, 2184-2191.	0.6	9

#	ARTICLE	IF	CITATIONS
109	Interrelationship of Sildenafil Treatment Effects on the Physiological and Psychosocial Aspects of Erectile Dysfunction of Mixed or Organic Etiology. <i>Journal of Sexual Medicine</i> , 2010, 7, 3170-3178.	0.6	28
110	Analysis of dyadic data: a guideline applied to erectile dysfunction. <i>Journal of Evaluation in Clinical Practice</i> , 2010, 16, 1340-1344.	1.8	2
111	Relationship between patient-reported disease severity in osteoarthritis and self-reported pain, function and work productivity. <i>Arthritis Research and Therapy</i> , 2010, 12, R162.	3.5	68
112	Exploratory Factor Analysis. , 2010, , 480-485.		2
113	Minimal Clinically Important Difference in the Fibromyalgia Impact Questionnaire. <i>Journal of Rheumatology</i> , 2009, 36, 1304-1311.	2.0	291
114	Estimating a Minimally Important Difference in Pulmonary Arterial Hypertension Following Treatment With Sildenafil. <i>Chest</i> , 2009, 135, 137-142.	0.8	77
115	Scoring Correspondence in Outcomes Related to Erectile Dysfunction Treatment on a 4-Point Scale (SCORE-4). <i>Journal of Sexual Medicine</i> , 2009, 6, 809-819.	0.6	25
116	Psychometric analysis of the Three-Factor Eating Questionnaire-R21: results from a large diverse sample of obese and non-obese participants. <i>International Journal of Obesity</i> , 2009, 33, 611-620.	3.4	334
117	Pain Responder Analysis: Use of Area Under the Curve to Enhance Interpretation of Clinical Trial Results. <i>Pain Practice</i> , 2009, 9, 348-353.	1.9	19
118	Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapyâ€“Kidney Symptom Indexâ€”Disease-Related Symptoms Scale. <i>Value in Health</i> , 2009, 12, 580-586.	0.3	7
119	Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. <i>Sleep Medicine</i> , 2009, 10, 766-770.	1.6	71
120	The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. <i>Sleep Medicine</i> , 2009, 10, 604-610.	1.6	87
121	Psychometric properties of a single-item scale to assess sleep quality among individuals with fibromyalgia. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 54.	2.4	119
122	Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. <i>Psychopharmacology</i> , 2008, 197, 371-377.	3.1	174
123	Analysis of single items on the Self-Esteem And Relationship questionnaire in men treated with sildenafil citrate for erectile dysfunction: results of two double-blind, placebo-controlled trials. <i>BJU International</i> , 2008, 101, 861-866.	2.5	13
124	Development and validation of the Well-being and Satisfaction of CAREgivers of Children with Diabetes Questionnaire (WE-CARE). <i>Health and Quality of Life Outcomes</i> , 2008, 6, 3.	2.4	16
125	A Practical Guide on Incorporating and Evaluating Patient-Reported Outcomes in Clinical Trials. <i>Clinical Research and Regulatory Affairs</i> , 2008, 25, 197-211.	2.1	12
126	Interpretation of a Self-Esteem Subscale for Erectile Dysfunction by Cumulative Logit Model. <i>Drug Information Journal</i> , 2007, 41, 723-732.	0.5	6

#	ARTICLE	IF	CITATIONS
127	Enhanced Interpretation of Instrument Scales Using the Rasch Model. <i>Drug Information Journal</i> , 2007, 41, 541-550.	0.5	6
128	Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire. <i>Addictive Behaviors</i> , 2007, 32, 912-923.	3.0	200
129	Multivariate framework of the Brief Questionnaire of Smoking Urges. <i>Drug and Alcohol Dependence</i> , 2007, 90, 234-242.	3.2	35
130	Validation of the Erection Hardness Score. <i>Journal of Sexual Medicine</i> , 2007, 4, 1626-1634.	0.6	266
131	Clinically meaningful improvement on the Self-Esteem And Relationship questionnaire in men with erectile dysfunction. <i>Quality of Life Research</i> , 2007, 16, 1203-1210.	3.1	19
132	Impact of Erectile Dysfunction on Confidence, Self-Esteem and Relationship Satisfaction After 9 Months of Sildenafil Citrate Treatment. <i>Journal of Urology</i> , 2006, 176, 2132-2137.	0.4	37
133	Self-Esteem, Confidence and Relationship Satisfaction of Men With Erectile Dysfunction Treated With Sildenafil Citrate: A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled Study in the United States. <i>Journal of Urology</i> , 2006, 175, 1058-1062.	0.4	87
134	Self-esteem, confidence, and relationships in men treated with sildenafil citrate for erectile dysfunction. <i>Journal of General Internal Medicine</i> , 2006, 21, 1069-1074.	2.6	35
135	Comparison Between Sildenafil-Treated Subjects with Erectile Dysfunction and Control Subjects on the Self-Esteem And Relationship Questionnaire. <i>Journal of Sexual Medicine</i> , 2006, 3, 274-282.	0.6	44
136	Sildenafil Citrate Improves Self-Esteem, Confidence, and Relationships in Men with Erectile Dysfunction: Results from an International, Multi-Center, Double-Blind, Placebo-Controlled Trial. <i>Journal of Sexual Medicine</i> , 2006, 3, 521-529.	0.6	80
137	Association between the Erectile Dysfunction Inventory of Treatment Satisfaction and the Self-Esteem and Relationship Questionnaire Following Treatment with Sildenafil Citrate for Men with Erectile Dysfunction. <i>Value in Health</i> , 2005, 8, S54-S60.	0.3	25
138	The Sexual Health Inventory for Men (SHIM): a 5-year review of research and clinical experience. <i>International Journal of Impotence Research</i> , 2005, 17, 307-319.	1.8	325
139	Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. <i>Current Medical Research and Opinion</i> , 2005, 21, 749-760.	1.9	62
140	Treatment responsiveness of the Self-Esteem And Relationship questionnaire in erectile dysfunction. <i>Urology</i> , 2003, 61, 888-892.	1.0	104
141	Assessing the Clinical Significance of Single Items Relative to Summated Scores. <i>Mayo Clinic Proceedings</i> , 2002, 77, 479-487.	3.0	207
142	Assessing the Clinical Significance of Single Items Relative to Summated Scores. <i>Mayo Clinic Proceedings</i> , 2002, 77, 479-487.	3.0	155
143	Assessing the clinical significance of single items relative to summated scores. <i>Mayo Clinic Proceedings</i> , 2002, 77, 479-87.	3.0	101
144	Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. <i>Urology</i> , 2000, 56, 477-481.	1.0	127

#	ARTICLE	IF	CITATIONS
145	Some Developments on the International Index of Erectile Function (IIEF). Drug Information Journal, 1999, 33, 179-190.	0.5	45
146	Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. International Journal of Impotence Research, 1999, 11, 319-326.	1.8	2,460
147	Diagnostic evaluation of the erectile function domain of the international index of erectile function. Urology, 1999, 54, 346-351.	1.0	921
148	An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Statistics in Medicine, 1998, 17, 1923-1942.	1.6	187
149	Large Trials vs Meta-analysis of Smaller Trials. JAMA - Journal of the American Medical Association, 1996, 276, 1332.	7.4	279
150	Patient-Reported Outcomes. , 0, , .		85
151	Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights. Pharmacoeconomics, 0, , .	3.3	0